PureIR
中文
Menu
About PureIR Game On

Listed Companies

Medical Devices

Consumer Healthcare

Healthcare Technology

Editorial Method

HKEX 02190 · Unpaid pilot profile

Zylox-Tonbridge

Zylox-Tonbridge Medical Technology Co., Ltd.

Zylox-Tonbridge focuses on the R&D, manufacturing and commercialisation of neurovascular and peripheral vascular interventional devices. First-half 2026 revenue was RMB632.036 million, gross margin was 73.4% and profit for the period was RMB179.110 million; at 30 June 2026, 69 products were available in China and its distribution network covered more than 3,500 hospitals.

Disclosure through2026-06-30 Page reviewed2026-09-12 Listed onHong Kong Stock Exchange
Page two · play it → Official investor-relations website ir@zyloxtb.com Financial highlights · 2026 interim results · PDF page 1

This is an unpaid PureIR pilot independently prepared from formal disclosure. The company did not commission or pay for the profile and did not participate in any rating or investment judgement.

Guiding interventional devices through the vascular pathway 00

Tap, or trace the vessel, to illuminate the interventional pathway

  1. 01R&D and registration
  2. 02Neurovascular intervention
  3. 03Peripheral intervention
  4. 04Global commercialisation

An editorial metaphor for the disclosed interventional-device R&D, portfolio and commercialisation pathway; it does not depict a device procedure or individual treatment outcome.

69 products Products available in China At 30 June 2026 3,500+ hospitals Hospitals covered by distribution network At 30 June 2026 1.35m+ devices Medical devices used clinically At 30 June 2026 Continue through the disclosure

Latest formal disclosure

2026 interim results

Formal interim results · unaudited Announcement published 20 August 2026

Interim revenue

RMB632.0m Up 31.1%; gross profit was RMB463.892 million and gross margin was 73.4%. Six months ended 30 June 2026 · RMB million HKEX · PDF page 1

Interim profit

RMB179.1m Up 47.8%; company-reported non-IFRS adjusted net profit was RMB188.812 million, up 43.7%. Six months ended 30 June 2026 · RMB million HKEX · PDF page 1

Overseas revenue

RMB70.6m Up 349.3%; the company disclosed that 94 products were distributed across 70 overseas countries and regions. Six months ended 30 June 2026 · RMB million HKEX · PDF page 4

The figures below are from the formal unaudited interim-results announcement for the six months ended 30 June 2026. Five-year trends use audited annual data through FY2025. The company did not declare an interim dividend for 2026.

Disclosure highlights

Latest disclosed facts

Cover of Zylox-Tonbridge 2025 annual report
Zylox-Tonbridge 2025 annual report · HKEX; latest data come from the 2026 interim results
01

Products available in China

69 products

At 30 June 2026 · products HKEX · PDF page 3
02

Hospitals covered by distribution network

3,500+ hospitals

At 30 June 2026 · hospitals HKEX · PDF page 3
03

Medical devices used clinically

1.35m+ devices

At 30 June 2026 · devices HKEX · PDF page 3

Disclosure reading

How to read the disclosure

PureIR disclosure synthesis

Two business lines form an interventional-device platform

The company has built R&D, manufacturing and commercialisation capabilities around neurovascular and peripheral vascular product lines; first-half 2026 revenue from the two businesses grew 20.2% and 40.0%, respectively.

HKEX · PDF page 2

PureIR disclosure synthesis

Portfolio breadth and hospital coverage connect commercialisation

At 30 June 2026, the company disclosed 69 products available in China, distribution coverage of more than 3,500 hospitals and more than 1.35 million devices used clinically. These figures indicate product and channel reach, not patient outcomes.

HKEX · PDF page 3

PureIR disclosure synthesis

Overseas business entered an acceleration phase

First-half 2026 overseas revenue was RMB70.6 million, up 349.3%. The company disclosed that 94 products were distributed across 70 overseas countries and regions, while partners covered more than 135 countries and regions.

HKEX · PDF page 4

PureIR disclosure synthesis

Profit and operating cash flow improved together

FY2025 revenue, gross profit, attributable profit and net operating cash flow all exceeded FY2024 levels, while first-half 2026 revenue and profit continued to grow year on year. Annual and interim periods are presented separately.

HKEX · PDF page 1

Business model

Business revenue

Neurovascular interventional devices revenue

RMB 676.253 million FY2025 PDF page 34

Peripheral vascular interventional devices revenue

RMB 379.395 million FY2025 PDF page 34

Annual series

Revenue mix by business (RMB)

Revenue mix by business (RMB), unit: RMB million 1,140 855 570 285 0 FY2021FY2022FY2023FY2024FY2025 Neurovascular interventional devices revenue FY2021: 112.3 RMB million Peripheral vascular interventional devices revenue FY2021: 65.6 RMB million Neurovascular interventional devices revenue FY2022: 233.4 RMB million Peripheral vascular interventional devices revenue FY2022: 100.7 RMB million Neurovascular interventional devices revenue FY2023: 381.8 RMB million Peripheral vascular interventional devices revenue FY2023: 144.7 RMB million Neurovascular interventional devices revenue FY2024: 528.5 RMB million Peripheral vascular interventional devices revenue FY2024: 252.4 RMB million Neurovascular interventional devices revenue FY2025: 676.3 RMB million Peripheral vascular interventional devices revenue FY2025: 379.4 RMB million
Period: complete fiscal years; business revenue follows company definitions; unit：RMB million；type: company disclosure. FY2021 formal disclosure, PDF page 158; FY2023 formal disclosure, PDF page 22; FY2025 formal disclosure, PDF page 34
View exact values and source pages
MetricPeriodValueSource
Neurovascular interventional devices revenueFY2021RMB 112.271 millionPDF page 158
Peripheral vascular interventional devices revenueFY2021RMB 65.641 millionPDF page 158
Neurovascular interventional devices revenueFY2022RMB 233.398 millionPDF page 22
Peripheral vascular interventional devices revenueFY2022RMB 100.692 millionPDF page 22
Neurovascular interventional devices revenueFY2023RMB 381.799 millionPDF page 22
Peripheral vascular interventional devices revenueFY2023RMB 144.653 millionPDF page 22
Neurovascular interventional devices revenueFY2024RMB 528.511 millionPDF page 34
Peripheral vascular interventional devices revenueFY2024RMB 252.419 millionPDF page 34
Neurovascular interventional devices revenueFY2025RMB 676.253 millionPDF page 34
Peripheral vascular interventional devices revenueFY2025RMB 379.395 millionPDF page 34

Structured disclosure

Financial performance

Gross profit

RMB 762.918 million FY2025 PDF page 8

Profit/(loss) attributable to equity holders

RMB 244.37 million FY2025 PDF page 8

Non-IFRS adjusted net profit/(loss)

RMB 273.071 million FY2025 PDF page 8

Annual series

Revenue and gross profit (RMB)

Revenue and gross profit (RMB), unit: RMB million 1,142 857 571 286 0 FY2021FY2022FY2023FY2024FY2025 Revenue FY2021: 177.9 RMB million Revenue FY2022: 334.1 RMB million Revenue FY2023: 527.8 RMB million Revenue FY2024: 782.5 RMB million Revenue FY2025: 1,057.5 RMB million Gross profit FY2021: 131.9 RMB million Gross profit FY2022: 252.7 RMB million Gross profit FY2023: 385.0 RMB million Gross profit FY2024: 559.9 RMB million Gross profit FY2025: 762.9 RMB million
Period: complete fiscal years; The fiscal year ends on 31 December. 2026H1 means the unaudited six months ended 30 June 2026.; unit：RMB million；type: company disclosure. FY2025 formal disclosure, PDF page 8

Annual series

Profit/(loss) attributable to equity holders (RMB)

Profit/(loss) attributable to equity holders (RMB), unit: RMB million 280 151 22 -106 -235 FY2021FY2022FY2023FY2024FY2025 Profit/(loss) attributable to equity holders FY2021: -199.7 RMB million Profit/(loss) attributable to equity holders FY2022: -113.6 RMB million Profit/(loss) attributable to equity holders FY2023: -78.7 RMB million Profit/(loss) attributable to equity holders FY2024: 100.3 RMB million Profit/(loss) attributable to equity holders FY2025: 244.4 RMB million
Period: complete fiscal years; The fiscal year ends on 31 December. 2026H1 means the unaudited six months ended 30 June 2026.; unit：RMB million；type: company disclosure. FY2025 formal disclosure, PDF page 8
View exact values and source pages
MetricPeriodValueSource
RevenueFY2021RMB 177.912 millionPDF page 8
RevenueFY2022RMB 334.09 millionPDF page 8
RevenueFY2023RMB 527.754 millionPDF page 8
RevenueFY2024RMB 782.476 millionPDF page 8
RevenueFY2025RMB 1,057.488 millionPDF page 8
Gross profitFY2021RMB 131.881 millionPDF page 8
Gross profitFY2022RMB 252.669 millionPDF page 8
Gross profitFY2023RMB 384.988 millionPDF page 8
Gross profitFY2024RMB 559.895 millionPDF page 8
Gross profitFY2025RMB 762.918 millionPDF page 8
Profit/(loss) attributable to equity holdersFY2021RMB -199.689 millionPDF page 8
Profit/(loss) attributable to equity holdersFY2022RMB -113.555 millionPDF page 8
Profit/(loss) attributable to equity holdersFY2023RMB -78.734 millionPDF page 8
Profit/(loss) attributable to equity holdersFY2024RMB 100.256 millionPDF page 8
Profit/(loss) attributable to equity holdersFY2025RMB 244.37 millionPDF page 8
Non-IFRS adjusted net profit/(loss)FY2021RMB -100.745 millionPDF page 8
Non-IFRS adjusted net profit/(loss)FY2022RMB -25.877 millionPDF page 8
Non-IFRS adjusted net profit/(loss)FY2023RMB 7.033 millionPDF page 8
Non-IFRS adjusted net profit/(loss)FY2024RMB 123.993 millionPDF page 8
Non-IFRS adjusted net profit/(loss)FY2025RMB 273.071 millionPDF page 8

Structured disclosure

Operating metrics

Products available in China

69 products 2026-06-30 PDF page 3

Hospitals covered by distribution network

3,500 hospitals 2026-06-30 PDF page 3

Medical devices used clinically

1,350,000 devices 2026-06-30 PDF page 3

Products distributed overseas

94 products 2026-06-30 PDF page 4

Overseas countries and regions reached

70 countries and regions 2026-06-30 PDF page 4

Countries and regions covered with partners

135 countries and regions 2026-06-30 PDF page 4
View exact values and source pages
MetricPeriodValueSource
Products available in China2026-06-3069 productsPDF page 3
Hospitals covered by distribution network2026-06-303,500 hospitalsDisclosed floor.PDF page 3
Medical devices used clinically2026-06-301,350,000 devicesThe company disclosed more than 1.35 million; the canonical value records the disclosed floor.PDF page 3
Products distributed overseas2026-06-3094 productsPDF page 4
Overseas countries and regions reached2026-06-3070 countries and regionsPDF page 4
Countries and regions covered with partners2026-06-30135 countries and regionsThe company disclosed more than 135; the canonical value records the disclosed floor.PDF page 4

Structured disclosure

Cash flow

Net cash from operating activities

RMB 384.862 million FY2025 PDF page 108

Available financial resources

RMB 2,388.9 million 2026-06-30 PDF page 46

Cash and cash equivalents

RMB 579.7 million 2026-06-30 PDF page 46

Term deposits

RMB 1,516.2 million 2026-06-30 PDF page 46

Annual series

Net cash from operating activities (RMB)

Net cash from operating activities (RMB), unit: RMB million 425 280 134 -11 -156 FY2021FY2022FY2023FY2024FY2025 Net cash from operating activities FY2021: -116.2 RMB million Net cash from operating activities FY2022: -91.3 RMB million Net cash from operating activities FY2023: 98.4 RMB million Net cash from operating activities FY2024: 174.1 RMB million Net cash from operating activities FY2025: 384.9 RMB million
Period: complete fiscal years; The fiscal year ends on 31 December. 2026H1 means the unaudited six months ended 30 June 2026.; unit：RMB million；type: company disclosure. FY2021 formal disclosure, PDF page 130; FY2023 formal disclosure, PDF page 160; FY2025 formal disclosure, PDF page 108
View exact values and source pages
MetricPeriodValueSource
Net cash from operating activitiesFY2021RMB -116.206 millionPDF page 130
Net cash from operating activitiesFY2022RMB -91.323 millionPDF page 160
Net cash from operating activitiesFY2023RMB 98.44 millionPDF page 160
Net cash from operating activitiesFY2024RMB 174.076 millionPDF page 108
Net cash from operating activitiesFY2025RMB 384.862 millionPDF page 108
Available financial resources2026-06-30RMB 2,388.9 millionPDF page 46
Cash and cash equivalents2026-06-30RMB 579.7 millionPDF page 46
Term deposits2026-06-30RMB 1,516.2 millionPDF page 46

Structured disclosure

Shareholder returns

Interim share-buyback consideration

HKD 116.266 million 2026H1 PDF page 51

Annual series

Final dividend

Final dividend, unit: RMB per share 1 1 1 0 0 FY2024FY2025 Final dividend FY2024: 0.1 RMB per share Final dividend FY2025: 0.22 RMB per share
Period: complete fiscal years; dividend status follows each year's formal disclosure; unit：RMB per share；type: company disclosure. FY2024 formal disclosure, PDF page 164; FY2025 formal disclosure, PDF page 23
View exact values and source pages
MetricPeriodValueSource
Final dividendFY2024RMB 0.1/shareThe FY2024 final dividend was approved at the 2025 AGM and paid.PDF page 164
Final dividendFY2025RMB 0.22/shareThe FY2025 final dividend was approved on 13 May 2026, with RMB72.899 million paid in the first half of 2026.PDF page 23
Interim share-buyback consideration2026H1HKD 116.266 millionDuring the six months ended 30 June 2026, 5,514,500 H shares were repurchased for this consideration, excluding commissions and other expenses. It is not comparable with per-share dividends.PDF page 51

Leadership profile

Senior management

Roles and biographies follow formal disclosure. Portraits are used only when published on the company’s official website.

Official portrait of Zylox-Tonbridge Chairman and CEO Jonathon Zhong Zhao

01 / 04

Jonathon Zhong Zhao

Chairman, Executive Director and Chief Executive Officer

Founded the Group in November 2012 and is responsible for overall management and business strategy. He has 29 years of pharmaceutical and medical-device experience, including drug-device combination product development at Guilford Pharmaceuticals and Johnson & Johnson's Cordis.

Biography: annual report PDF page 41 Portrait: official company website
1 / 4

Official market reference

Latest quote on HKEX

PureIR does not display or redistribute market-price data.

View 02190 on HKEX ↗

Formal disclosure

Principal risks

Product concentration

FY2025 revenue remained substantially reliant on a limited number of commercialised products; changes in demand, access or competition affecting those products may affect performance.

HKEX · PDF page 9

R&D and regulatory conversion

Future growth depends on product candidates completing clinical development, securing regulatory approval and being commercialised successfully; failure or material delay may affect the business.

HKEX · PDF page 9

VBP, tendering and pricing pressure

Medical-device markets face competition, tendering and pricing pressure, which may affect product prices, market share and profitability.

HKEX · PDF page 9

Manufacturing quality and regulation

Product manufacturing is complex and subject to strict quality controls; supply, logistics, manufacturing or quality issues may affect the business, while the medical-device industry is extensively regulated and exposed to rule changes.

HKEX · PDF page 10

Evidence

Formal sources and public data

Annual Report 2025193 PDF pagesAnnual Report 2023241 PDF pagesAnnual Report 2021201 PDF pagesInterim Results for the Six Months Ended June 30, 202658 PDF pagesPoll Results of the Annual General Meeting7 PDF pagesUpdate on Share Repurchase2 PDF pagesDownload structured JSON →